Mississauga, ON -- (SBWire) -- 05/20/2015 --AllPennyStocks.com Media, Inc. (http://www.AllPennyStocks.com/) announces its latest article titled "Lpath Shares Crash as Phase 2 Trial for Eye Disease Misses Endpoints."
Companies mentioned in this article include Lpath, Inc. (NASDAQ:LPTN) and Pfizer (NYSE:PFE).
Article Excerpt:
Biotechnology stocks can be as volatile as anything in the market, especially those that are relatively thinly traded. Positive data – or even expectations of positive data – from a clinical trial can send valuations soaring. The opposite is, of course, equally true. For Lpath, Inc. (NASDAQ:LPTN), a company focused on lipid-targeted therapeutics, the stock price got a double whammy in the last two months, erasing most of the company's value.
Shares of LPTN have been in a slow and steady slide since hitting $10.85 in early 2011, but managed to rise to a five-month high in March at $3.75 ahead of results from a Phase 2a trial of drug candidate ASONEP for treating kidney cancer patients that had failed previous therapy. In a matter of days, the stock lost more than 30 percent of its value from that high as the trial failed to meet its primary endpoint of 25 out of 39 patients remaining progression free two months after treatment, although there were some positives to be taken from the results.
The full version of this article can be found at:
http://www.allpennystocks.com/aps_us/special-reports/535/lpath-shares-crash-as-phase-2-trial-for-eye-disease-misses-endpoints.htm
About AllPennyStocks.com
AllPennyStocks.com is focused on the small-cap / penny stock market and has become a reputable name in the investment community. AllPennyStocks.com runs a Canadian and US site to provide investors in Canada as well as the United States with informative and unique content and information. AllPennyStocks.com runs daily technical penny stocks to watch, has a daily market write-up, provides company spotlights, runs unique most active pages strictly for penny stocks trading on the TSX, TSX Venture, NASDAQ and OTC BB, and much more information for the average investor.
AllPennyStocks.com also runs an email newsletter that aims to uncover stocks that are still under the radar of most investors. Criteria AllPennyStocks.com looks for includes strong revenues, a seasoned management, innovative business plans, among many others. AllPennyStocks.com also looks for companies that announce breaking news, recent 52-week highs/lows, technical breakouts, and other favorable corporate information.
Investors are encouraged to subscribe to the AllPennyStocks.com FREE e-mail newsletter and see what tens of thousands of other investors have already been receiving since 1999. Investors can receive their free newsletter subscription by clicking here: http://www.allpennystocks.com/aps_common/newsletter_free.asp.
Contact:
AllPennyStocks.com Media, Inc.
Peter Szafranski -- President
Phone: 905-361-5680
E-Mail: peter@allpennystocks.com
Websites: http://www.allpennystocks.com / http://www.bullishinvestor.com
Note: AllPennyStocks.com has not received compensation for carrying the above-mentioned company; a full disclaimer can be viewed here: http://www.allpennystocks.com/aps_common/disclaimer.asp.
All Penny Stocks.com News: Lpath Shares Crash as Phase 2 Trial for Eye Disease Misses Endpoints